Muscle Loss from GLP-1 Drugs Like Ozempic May Be Less Severe Than Previously Thought
Emerging research indicates that muscle loss associated with GLP-1 drugs like Ozempic may be less significant than previously estimated, with implications for patient safety and long-term use.
New Insights on Muscle Loss with GLP-1 Medications
Recent research suggests that muscle loss associated with GLP-1 receptor agonists such as Ozempic may not be as significant as earlier estimates. While past studies indicated that adults could lose between 5-15% of their body weight with these drugs, a considerable portion of that weight loss was attributed to muscle reduction.
A new study conducted using a mouse model found that muscle loss was around 10%, involving not only skeletal muscles but also other tissues like the liver, which decreased in size by nearly half. This indicates that weight loss from GLP-1 medications may involve complex physiological changes.
Key Findings:
- Muscle loss from GLP-1 drugs may be less than previously believed.
- The reduction affects various tissues, including the liver.
- Muscle strength may decline even if muscle size remains unchanged.
Expert Opinions and Future Directions
Dr. Seth Kipnis emphasizes that some muscle loss is inevitable but stresses the importance of adequate nutrition. Meanwhile, Dr. Kais Rona highlights the need for human trials to better understand these effects, including impacts on muscle function and organ health.
Ongoing research aims to determine whether specific body areas are more vulnerable to muscle loss and how to develop strategies to prevent it, ensuring safer long-term use of GLP-1 medications.
==References==
- Research in Cell Metabolism
- Study in The Lancet
- Expert commentary by Dr. Seth Kipnis
- Interview with Dr. Kais Rona
This evolving research underscores the importance of working with healthcare professionals to monitor muscle health during GLP-1 medication therapy.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Skin Biomarkers as a Promising Tool for Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS)
Innovative research indicates skin-based biomarkers could enable earlier and less invasive diagnosis of amyotrophic lateral sclerosis (ALS), improving disease management and understanding.
New Insights into Brain Networks Associated with Psychopathy
Recent research uncovers the brain structural differences linked to psychopathy, highlighting abnormal regions associated with antisocial behaviors and emotional regulation. These findings enhance our understanding of the neurobiological basis of psychopathic traits.
Alterations in Myelin Sheath Proteins Disrupt Nerve Signaling in Alzheimer's Disease
New research uncovers how changes in myelin sheath proteins disrupt nerve signaling in Alzheimer's disease, offering potential targets for future therapies.
Enhancing Surgical Outcomes Through Removal of Recovery Barriers
A groundbreaking study shows that preoperative psychological evaluations can identify and mitigate barriers to recovery, leading to better surgical outcomes and enhanced patient adherence to postoperative plans.